Survival analysis comparing fixed low-dose and moderate-dose regimens of hydroxyurea for secondary stroke prevention. The proportion of participants without recurrent stroke, TIA, or death was not different between groups at a median follow-up of 1.6 years (interquartile range, 1.0-2.3). See Figure 2 in the article by Abdullahi et al that begins on page 825.